(Q46234082)

20 December 2017

title

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects (English)

1 reference

20 December 2017

1 reference

1 reference

1 reference

3

1 reference

20 December 2017

author name string

Nagy A Farid

1

1 reference

20 December 2017

David S Small

2

1 reference

20 December 2017

Joseph A Jakubowski

4

1 reference

20 December 2017

John T Brandt

5

1 reference

20 December 2017

Ying G Li

6

1 reference

20 December 2017

C Steven Ernest

7

1 reference

20 December 2017

Daniel E Salazar

8

1 reference

20 December 2017

Christopher S Konkoy

9

1 reference

20 December 2017

Kenneth J Winters

10

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

20 December 2017

published in

Pharmacotherapy

1 reference

20 December 2017

volume

28

1 reference

20 December 2017

page(s)

1483-1494

1 reference

20 December 2017

issue

12

1 reference

20 December 2017

Biology and pharmacology of the platelet P2Y12 receptor

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

The disposition of prasugrel, a novel thienopyridine, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

Current progress on esterases: from molecular structure to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

The human intestinal cytochrome P450 "pie".

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.12.1483

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.12.1483

1 reference

20 December 2017

PubMed ID

19025429

1 reference

20 December 2017